GI Oncology Now

?? Neuroendocrine tumor diagnosis is often delayed due to misdiagnosis or nonspecific symptoms, resulting in the occurrence of metastases in patients. ?? Learn how a study developed a blood-based, non-invasive classifier to serve as a tool for the detection and treatment response of patients with NETs:

?? A recent retrospective study has evaluated patient data to analyze the link between tumor burden score, patient survival, and disease recurrence in #hepatocellularcarcinoma. ?? Patients with high TBS had worse OS and recurrence-free survival:

?? While surgical procedures like liver resection can be curative for early-stage patients with hepatocellular carcinoma, the relapse rate is high in the first five years post-resection. ?? Learn what a recent analysis found about the link between depth of tumor regression and relapse-free survival:

?? A recent study performed a review and meta-analysis of previously gathered clinical trial data to compare 1st line chemotherapy for advanced pancreatic ductal adenocarcinoma with other treatment options for #PDAC. ?? Learn more about the efficacy and toxicity of various treatment options: https://buff.ly/40XY1SR #PancreaticCancerAwareness

?? Jazz Pharmaceuticals' zanidatamab has gained accelerated approval by the FDA for the treatment of metastatic HER2+ biliary tract cancer. ?? Learn about the results of the HERIZON-BTC-01 trial which led to the approval, and what's next for this treatment:

? We spoke with Kimmie Ng, director of Dana-Farber Cancer Institute's Young-Onset Colorectal Cancer Center, on her unique path to becoming a GI oncologist, from her early passion for classical piano at The Juilliard School to formative medical training at institutions such as Yale University and the University of Pennsylvania. ?? Read about Dr. Ng's inspiring journey into the field of oncology: https://buff.ly/3CPiqPW

?? Despite its use as a common prognostic #biomarker for gastric cancer, the predictive values of NLRs still remain unclear for patients who undergo #NAC. ?? A recent systematic review and meta-analysis utilized multiple databases to evaluate the relationship between NLR and the prognosis of patients with #gastric cancer who receive NAC:

??? Pancreatic tumors are surrounded by a so-called immune desert, in which the microenvironment surrounding the tumors has suppressed immune activity. ?? Learn how a recent study sought to use #nivolumab with #entinostat to disrupt this environment: #PancreaticCancerAwareness

?? Watch Dr. Richard Finn give an overview of the HIMALAYA study, as well as LEAP-012 and IMbrave050, in our interview on some of the top GI data from this year's #ESMO24 conference. ?? HIMALAYA demonstrated the benefits of STRIDE over #sorafenib for HCC: https://buff.ly/3YvYwRA

?? Dr. Richard Finn of UCLA Health reviews key highlights in #livercancer from #ESMO24, including the LEAP-012 trial on #lenvatinib with #chemoembolization versus placebo and chemoembolization: https://buff.ly/3YvYwRA